Recently,BIOCHINA2025 was grandly held from March 13 to 15 at the Suzhou International Expo Center, where the "BIOCHINA Awards 2024: The 9th EMBio Annual Industry Awards" ceremony took place.METiS TechBio Honored with the "2024 Innovative Breakthrough Enterprise" Award at the BIOCHINA Awards for Outstanding Technological Innovation.

BIOCHINA, as a leading platform for exchange and cooperation in the biotechnology industry, collaborates with a professional review committee. Adhering to the principles of fairness, impartiality, and transparency, it conducts comprehensive evaluations based on multi-dimensional real data. The aim is to discover innovative forces in the biopharmaceutical industry and promote industrial development.

At this conference,Dr. Lai Caida, Co-founder & CEO of METiS TechBio, as the planner of the special session on breakthroughs in mRNA new technologies, delivered a keynote speech titled "AI Technology Empowering mRNA Drug Development," providing an in-depth analysis of the cutting-edge applications of AI technology in the mRNA drug field.

mRNA and AI Integration: Opportunities in Drug Development

As an emerging biotechnology, mRNA therapy has received global attention due to its unique advantages. The success of the COVID-19 vaccine has fully validated the potential of mRNA technology, showcasing its characteristics of rapid preparation, low cost, and high safety. However, the development of mRNA drugs still faces technical challenges, and the deep application of AI technology provides new opportunities for solutions.

Thanks to its expertise in the RNA field, innovative AI generative models, and high-throughput validation capabilities, METiS TechBio has successfully developed an AI-driven mRNA design and high-throughput synthesis platform — the AiRNA Platform.ThroughDe NovoDesign RNA biological components,Development of AI Algorithms Combined with High-Throughput Experimental Screening, METiS TechBioBuilt an innovative set of technical solutions,ForKey Issues in mRNA TherapyProvided innovative solutions.

At the same time, as a global leaderThe "AI + Nanomaterials" technology platform has also enabled METiS TechBio to achieve breakthrough success in the development of targeted nanodelivery materials. The company's...Create heart, muscle, brain-targeted and other multi-organ targeted delivery,Targeted delivery efficiency in multiple organs such as the liver and lungsExceeding industry standards by more than 20 times,Breakthrough in RNA drugs for precisionIn terms of delivery"Pinch Point" Problem.

At the 2024 International mRNA Health Conference,The company's poster "Organ-Specific Delivery of a mRNA-Encoded Bispecific T Cell Engager Targeting Glypican-3 in Hepatocellular Carcinoma" stood out from hundreds of reports and won the conference's "Excellent Poster Award."Notably, this conference was jointly planned and organized by international academic and industry experts, including Nobel laureate Katalin Karikó. This honor fully demonstrates METiS TechBio's outstanding R&D strength and innovation capabilities in the fields of nucleic acid drugs and precision delivery.

MTS105 is an mRNA-encoded bispecific T-cell engager (BiTE) based on METiS TechBio's first-in-class tumor-targeting LNP delivery technology. Preclinical data show that MTS105 achieves high concentrations of localized specific expression in liver and tumor tissues, while demonstrating good safety and tolerability. The project was included as a major project in the 2022 National Biomedicine Innovation Center’s Nucleic Acid Drug "Open Challenge" Technology Breakthrough Initiative.AndOfficially launched human trials in November 2024, marking an important step in clinical progress.

The Future of AI: From Curing Diseases to Changing the World

At the 2024 Technology Summit, another Nobel laureate and CEO of DeepMind, Demis Hassabis, stated that AI will cure all diseases in the near future: "Artificial intelligence will be epoch-making, soon solving climate and energy problems, and even curing all diseases."

Learn More About METiS TechBio

METiS TechBio Included in "Top 30 AIGC Application Innovations of 2024" List